NanGenex, member of the DRGT Group, is a Budapest based science driven technology company.

The Group’s proprietary Super-API drug development platform enables NanGenex to develop new generation of high-value drugs with significant performance benefits over conventional approaches.

The technology provides the means to generate Super-API drugs by altering certain physico-chemical properties of the APIs to substantially improve their clinical utility.